CBOE Holdings Inc.

05/13/2019 | Press release | Distributed by Public on 05/13/2019 10:36

Abiomed Reports FDA Approval Of Impella 5.0, Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

Cboe - Market News Story

Abiomed Reports FDA Approval Of Impella 5.0, Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

Benzinga Newsdesk 5/13/2019 11:00:35 AM